Treatment of HCV allows for sustained removal from the liver transplant waiting list

https://www.eurekalert.org/pub_releases/2017-04/eaft-toh041117.php

Public Release: 21-Apr-2017
Treatment of HCV allows for sustained removal from the liver transplant waiting list
ILC 2017: Of 38 patients (26.7 percent) that were delisted due to clinical improvement, one died as a result of rapidly progressing hepatocellular carcinoma while two (5.2 percent) other patients had to be relisted or considered for relisting
European Association for the Study of the Liver

The Netherlands: A new European study presented today demonstrated that patients with chronic Hepatitis C virus (HCV) and severe liver damage, taken off the liver transplant list as a result of successful direct-acting antiviral (DAA) therapy, had a favourable outcome over a year later. The study, presented at The International Liver Congress™ 2017 in Amsterdam, The Netherlands, showed that 38 of 142 patients (26.7%) could be removed from the waiting list due to clinical improvement. Of the 38 patients taken off of the transplant list, one (2.6%) died as a result of rapidly progressing HCC while two other patients (5.2%) had to be relisted or considered for relisting.

•••••